Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.
about
Antimicrobial drug prescribing for pneumonia in ambulatory carePathophysiology and treatment of bacterial meningitisFluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trialsIn vitro activities of the Rx-01 oxazolidinones against hospital and community pathogensEffectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trialsNational and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance studyDifferences between ceftriaxone and cefotaxime: microbiological inconsistenciesPrevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitisUsing hospital antibiogram data to assess regional pneumococcal resistance to antibioticsPharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh modelImmunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in MiceRisk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.Expansion and evolution of the Streptococcus pneumoniae Spain9V-ST156 clonal complex in Poland.New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitalsTelithromycin: a novel agent for the treatment of community-acquired upper respiratory infectionsFractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites.Novel antibacterial class.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Inhibition of T cells provides protection against early invasive pneumococcal diseaseAntimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulenceTelithromycin: an oral ketolide for respiratory infections.Ramoplanin: a lipoglycodepsipeptide antibiotic.Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniaeFluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.The macrolides.Delafloxacin: design, development and potential place in therapyChanges in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.Resistance among Streptococcus pneumoniae: Implications for drug selection.Delafloxacin for the treatment of respiratory and skin infections.Antimicrobial activities of Eugenia caryophyllata extract and its major chemical constituent eugenol against Streptococcus pneumoniae.Antibiotics in the treatment of acute exacerbations of chronic bronchitis.Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.The evolution and role of macrolides in infectious diseases.Quinupristin/dalfopristin.
P2860
Q24620235-3DD771C5-8782-4121-9C1A-228DC2479E13Q24628983-FF8B5765-E1B0-41CC-9CD1-2A3A91FE937DQ24653970-722D30AC-516D-4264-A7B0-B47371257D1BQ24656140-22C73823-C20C-41A2-B063-BF7F5006B046Q24657558-2C30732A-6EC2-4611-B885-7097D42BCB71Q24682283-395837AE-3870-45A6-B3B3-1DB14B784F4BQ28261698-03F73534-E865-4E54-8595-D50BD0E53D12Q28757559-CD7235DA-C376-4505-90E0-277526886267Q30772203-3B24FD30-6A12-4CAA-B0A9-A80FAE4B5D4AQ33555366-4C8650C9-761C-4E42-81FB-C84F800686D9Q33675920-FF88BE44-A381-40C4-AB26-2D1317C23D67Q33752905-E8E268EE-C09D-4BDC-A63A-7974832F999CQ33826273-11571510-A76B-4267-8EB0-B538E928F360Q33836747-7DCB5170-D156-41B3-8A7B-66F3E69CEE58Q33945038-16534B7D-AD98-4201-9320-F04C9D00A604Q33983513-02E70699-02C2-4325-BC30-D91BC80FA1E0Q34107785-160AF46B-190A-430B-9FE5-6EE5A3F91196Q34113933-7E0A1E8C-D4AA-457D-9327-9E1DA303E7A7Q34195993-39BFD227-1DA6-412D-BFF7-0E9ECC72D3B1Q34230515-9744A750-A14B-4822-88BB-864242144508Q34281970-7A8F78F5-43C5-451E-9AB4-ADACCF749FBEQ34309777-DFD566C5-5FBC-49B6-A7F3-C84722E37B18Q34347889-C4079525-9FC3-41B1-A69C-3CAF094CFDE4Q34362097-8CC7AF5B-9C0D-46CE-867D-C31DE8350C5CQ34401542-F003E0E3-976E-4E6C-BE97-03EE6D8FDBC0Q34405651-DA520F85-4E45-40D3-AAFD-B3CB19A702CCQ34469936-17DC593E-9118-4FD4-AE14-045961858A51Q34470043-28C8C67E-8BF5-4A1D-B8FF-A247CD77A1BEQ34498620-1C0DD560-898A-44CF-BEA9-1BC3DEBF6AD4Q34519125-FAA23671-3E3B-4CB5-8FFD-DC11C2AF01A1Q34554381-D1331CB7-5251-468F-863C-E1E697CFDE5DQ34596707-D31D03E5-2E65-478A-A521-4356BADB5D8DQ34658646-C9A94CEA-8AFF-4570-8FC3-6410093C4F56Q34667588-83B5D465-B4A3-4674-8823-A17DD6B87DC9Q34675266-57E2F73D-9A4A-4F32-B1E5-736F1D36AB69Q34706968-F150CD44-3321-49B0-A6DC-C5D7FA7CE97DQ34749258-C7F42473-E381-484D-ADEC-CBBF0EECCE36Q34752032-61241AB8-F09B-4609-BB76-0D136F06C4DCQ34768513-34211646-D9F8-4EB5-89BC-0ABB83509C88Q34789160-3AB3CA7E-D938-498C-8BD2-E5C8C2D07BF3
P2860
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antimicrobial resistance among ...... stance rates since 1994--1995.
@ast
Antimicrobial resistance among ...... stance rates since 1994--1995.
@en
type
label
Antimicrobial resistance among ...... stance rates since 1994--1995.
@ast
Antimicrobial resistance among ...... stance rates since 1994--1995.
@en
prefLabel
Antimicrobial resistance among ...... stance rates since 1994--1995.
@ast
Antimicrobial resistance among ...... stance rates since 1994--1995.
@en
P2093
P2860
P1476
Antimicrobial resistance among ...... istance rates since 1994--1995
@en
P2093
P2860
P304
P356
10.1128/AAC.45.6.1721-1729.2001
P407
P577
2001-06-01T00:00:00Z